- In light of recent progress in the genomics of complex traits, where do we stand with glomerular disease?
- The role of renal biopsy and clinical pathologic correlations
- Treatment of classes III and IV is divided into two phases: induction and maintenance
- Maintenance therapy of proliferative lupus nephritis
- Treatment of class V—membranous lupus nephropathy
- Future Therapies
- References
-
1.
Danila. Renal damage is the most important predictor of mortality: Data from a multiethnic US cohort. Rheumatology 2009; 48:542–545.
-
2.
Gourley MF, et al.. Methylprednisolone and cyclophosphamide, alone or in combination in patients with lupus nephritis: A RCT. Ann Intern Med 1996; 125:549–557.
-
3.
Houssiau FA, et al.. Immunosuppressive therapy in lupus nephritis: The Eurolupus Nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46:2121–2131.
-
4.
Appel GB, et al.. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20:1103–1112.
-
5.
Contreras G, et al.. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350:971–980.
-
6.
Houssiau FA, et al.. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010; 69:2083 –2089.
-
7.
Dooley MA, et al.. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365:1886–1889.
-
8.
Rovin. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis. N Engl J Med 2012; 64:1215–1226.
-
9.
Weidenbusch. Beyond the LUNAR trial: Efficacy of rituximab in refractory lupus nephritis. Transplantation 2013; 28:106–111.
-
10.
Austin HA 3rd, et al.. Randomized controlled trial of prednisone, cyclophosphamide and cyclosporine in lupus membranous nephritis. J Am Soc Nephrol 2009; 20:901–911.
-
11.
Radhakrishnan J, et al.. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010; 77:152–160.
-
12.
Condon MB, et al.. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate but no oral steroids. Ann Rheum Dis 2013; 72:1280–1286.
-
13.
Lui. Multitargeted treatment for induction of lupus nephritis: A randomized trial. Ann Intern Med 2015; 162:18–26.
-
14.
Rönnblom L, Alm GV, Eloranta ML. The type I interferon assists in the development of lupus. Semin Immunol 2011; 23:113–121.
-
15.
Feng X, et al.. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54:2951–2962.
-
16.
Furie R, et al.. Anifrolumab, an anti–interferon-alpha receptor monoclonal antibody in moderate to severe SLE. Arthritis Rheum 2017; 69:376–386.
-
17.
Mossner E, et al.. Increasing the efficacy of CD20 antibody therapy through engineering a new type 2 anti-20 antibody with enhanced direct and immune effector cell mediated B cell cytotoxicity. Blood 2010; 115:4393–4402.
Lupus Nephritis in 2017: An Update
Renal involvement is clinically apparent in approximately 50% of systemic lupus erythematosis (SLE) patients and a frequent cause of significant morbidity and mortality (
© 2021 American Society of Nephrology | All Rights Reserved
Powered by: PubFactory